Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Ofatumumab [USAN:INN:BAN:JAN]
RN: 679818-59-8
UNII: M95KG522R0

Notes

  • An anti-CD20 MAb used as an antineoplastic agent; in phase 1-2 clinical trials.
  • An anti-CD20 MAb; in phase 1-2 clinical trials.

    NCI: A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development. (NCI Thesaurus)

Molecular Formula

  • C6480-N10022-N1742-O2020-S44
 

Classification Codes

  • Antineoplastic Agents
  • Treatment of Chronic Lymphocytic Leukemia

Names and Synonyms

Name of Substance

  • Ofatumumab [USAN:INN:BAN:JAN]

Synonyms

  • Arzerra
  • Arzerra Injection
  • GSK 1841157
  • GSK1841157
  • HSDB 8170
  • HuMax-CD20
  • HuMax-CD20, 2F2
  • Immunoglobulin G1, anti-(human CD20 (antigen))(human monoclonal HuMax-CD20 heavy chain), disulfide with human monoclonal HuMax-CD20 kappa-chain, dimer
  • Ofatumumab
  • UNII-M95KG522R0

Registry Numbers

CAS Registry Number

  • 679818-59-8

FDA UNII

  • M95KG522R0

System Generated Number

  • 0679818598